Recent Advances in the Discovery of Small Molecule Inhibitors of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) as a Therapeutic Target for Inflammation and Oncology Disorders

Citations Over TimeTop 10% of 2014 papers

Abstract

IRAK4, a serine/threonine kinase, plays a key role in both inflammation and oncology diseases. Herein, we summarize the compelling biology surrounding the IRAK4 signaling node in disease, review key structural features of IRAK4 including selectivity challenges, and describe efforts to discover clinically viable IRAK4 inhibitors. Finally, a view of knowledge gained and remaining challenges is provided.

Related Papers

• → Origin and physiological roles of inflammation(2008)6,240 cited
• → Dermal Drivers of Injury-Induced Inflammation: Contribution of Adipocytes and Fibroblasts(2021)46 cited
• → MK2 Signaling: Lessons on Tissue Specificity in Modulation of Inflammation(2010)16 cited
• → Inflammation(2022)3 cited
• → Inflammation(2010)1 cited